Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Capricor Therapeutics Q4 2025 Earnings Call - BLA Accepted, PDUFA Aug 22 2026
Capricor walked into 2026 with the outcome every biotech CFO and patient advocate prays for. The FDA has accepted the companys Class 2 BLA resubmission for Deramiocel and set a PDUFA target action dat...
- FDA accepted Capricors Class 2 BLA resubmission for Deramiocel, PDUFA date set for August 22, 2026.
- HOPE-3 pivotal trial (n=106) met primary endpoint Performance of the Upper Limb and all Type I error controlled secondaries.
- Left ventricular ejection fraction showed a 91 percent slowing of disease progression overall, with a p value of 0.01 in the cardiomyopathy subgroup.
- +16 more takeaways
Silvaco Q4 FY2025 Earnings Call - FTCO AI traction and Mixel IP turbocharge bookings, targeting profitability
Silvaco closed Q4 FY2025 with a clear inflection: bookings and revenue landed near the top of guidance, driven by a faster-than-expected commercial ramp of FTCO, the companys AI-driven process develop...
- Q4 bookings were $18.3 million, at the high end of guidance; Q4 revenue was also $18.3 million, above guidance.
- TCAD delivered a large sequential rebound: bookings rose 70% to $9.2 million and revenue rose 34% to $8.7 million, driven by FTCO adoption.
- FTCO, Silvacos AI-driven process development platform, signed a second customer in Asia in Q4, and management says adoption is accelerating beyond memory use cases.
- +12 more takeaways
Atlanticus Holdings Corporation Fourth Quarter 2025 Earnings Call - Mercury Deal Doubles Balance Sheet, Integration Ahead of Plan
Atlanticus closed a transformational 2025 by completing the Mercury Financial acquisition, roughly doubling its balance sheet to about $7 billion and adding 1.3 million customers. Management says inte...
- Mercury acquisition completed in 2025, roughly doubling Atlanticus’s balance sheet to about $7 billion and adding more than 1.3 million customers.
- Management says Phase one of Mercury portfolio repositioning is complete and is performing better than modeled, with additional phases continuing through 2026.
- Atlanticus acquired a $165 million retail credit portfolio during the quarter, strengthening its second-look point-of-sale position.
- +15 more takeaways
Allogene Therapeutics Q4 2025 Earnings Call - Data-Driven Year Ahead, ALPHA3 MRD Readout in April and ALLO-329 PoC in June
Allogene enters 2026 with a tight, evidence-first playbook: an April interim MRD readout from ALPHA3 that could validate allogeneic CAR T as frontline consolidation in large B-cell lymphoma, and a Jun...
- April 2026: interim MRD futility analysis from ALPHA3 will report MRD clearance in 24 patients, 12 per arm, plus early safety; company has set an internal meaningful threshold at a 25% to 30% absolute delta in MRD conversion.
- June 2026: proof of concept readout expected for ALLO-329 in the phase 1 RESOLUTION trial, with translational and early clinical signals from dose level 1.
- ALLO-329 is engineered as a dual CD19/CD70 allogeneic CAR T with Dagger technology, designed to enable meaningful expansion and persistence at low, or possibly no, conventional lymphodepletion.
- +12 more takeaways
ServiceTitan Fourth Quarter Fiscal Year 2026 Earnings Call - Max pilot promises step-change in AI-driven monetization
ServiceTitan closed FY26 with $961m in revenue, a $1bn-plus run rate milestone, stronger margins, and a clear pivot: turn the platform into an agentic operating system via Max. Management leaned hard ...
- Company exceeded $1 billion annualized revenue run rate, finishing FY26 with $961m in revenue, up 24% year-over-year for the full year.
- Q4 FY26 results: GTV $19.8bn (up 16% yoy), total revenue $254m (up 21% yoy), subscription revenue $192m (up 23% yoy).
- Platform gross margin improved to 80% in Q4, up ~330 basis points year-over-year; total gross margin 73.8%, up ~360 basis points.
- +17 more takeaways
KinderCare Learning Fourth Quarter 2025 Earnings Call - Enrollment Slump Forces Lower 2026 EBITDA Guide
Tom Wyatt returned as CEO in December and opened the call with a blunt assessment: execution slipped and enrollment fell short of expectations. Q4 and full-year 2025 results were propped up by an extr...
- Tom Wyatt returned as CEO in December and said the company fell short on consistency and execution, particularly at the center level.
- Q4 2025 revenue was $688 million, up 6% year-over-year, but that includes a $45 million contribution from a 53rd week; on a comparable basis revenue was essentially flat.
- Q4 adjusted EBITDA was $68 million, which included approximately $12 million from the extra week; adjusted EPS was $0.12.
- +12 more takeaways
Pixelworks FY2025 Earnings Call - Shanghai Sale Recasts Pixelworks as Cash-Rich, Asset-Light Licensing Company
Pixelworks used a January 6, 2026 closing of its Shanghai semiconductor subsidiary sale to pivot from a capital-intensive China hardware business to a lean, global technology licensing company centere...
- Pixelworks closed sale of its Shanghai semiconductor subsidiary on January 6, 2026, receiving approximately $51 million in net cash proceeds.
- Had the sale and prior Q4 transactions closed before year end, the company would have entered 2026 with about $62 million in cash; management now expects roughly $58 million as of March 31 after transaction costs, severances, and bonuses.
- Continuing operations revenue for fiscal 2025 was about $690,000, comprised entirely of TrueCut Motion platform and motion grading services; the semiconductor business is presented as discontinued operations.
- +12 more takeaways
Adobe Q1 FY2026 Earnings Call - AI-driven MAU surge offsets stock decline as CEO announces transition
Adobe opened FY2026 with a clean, AI-flavored quarter. Revenue hit $6.4 billion, up 11% in constant currency, non-GAAP EPS rose 19% to $6.06, and total ARR reached $26.06 billion. The company is seein...
- CEO succession announced: Shantanu Narayen will transition from CEO over the coming months and remain Chair to support the handoff.
- Q1 top line: Revenue $6.40 billion, up 12% reported and 11% in constant currency.
- Profitability: GAAP EPS $4.60, non-GAAP EPS $6.06 (up 19% YoY); GAAP operating margin 37.8%, non-GAAP operating margin 47.4%.
- +13 more takeaways
The Oncology Institute Q4 2025 Earnings Call - Delegated Capitation and Pharmacy Dispensing Drive First Adjusted EBITDA Profit
The Oncology Institute closed 2025 by reporting its first positive adjusted EBITDA quarter, powered by rapid expansion of delegated capitation in Florida and a surging Part D dispensing business. Reve...
- TOI reported its first positive adjusted EBITDA quarter as a public company in Q4 2025, with adjusted EBITDA of $147,000, and management is reaffirming full-year positive adjusted EBITDA for 2026.
- Full year 2025 revenue was $502.7 million, up approximately 27.8% year-over-year, the first time TOI surpassed $500 million in revenue.
- Pharmacy/Part D was the growth engine, with full-year pharmacy revenue of $269.2 million (up 49.6% YoY) and pharmacy gross profit contributing nearly $50 million for the year.
- +14 more takeaways
Identiv Q4 2025 Earnings Call - Exclusive IFCO BLE deal sets stage for 100M-unit scale-up, near-term margin variability
Identiv closed fiscal 2025 with a quarter that beat guidance, showing clear operational progress after a two-year manufacturing transition from Singapore to Thailand. Q4 revenue was $6.2 million, GAAP...
- Signed a multi-year exclusive supply agreement with IFCO to manufacture specialized BLE smart labels, with Identiv as sole supplier for committed volumes.
- Capacity build targets 100 million BLE labels per year, with IFCO aiming to tag a pool of more than 400 million reusable containers and replacing ~10% annually.
- Full-scale mass production for the IFCO program is expected later in 2026, subject to completion of development milestones and pilot testing.
- +12 more takeaways